COVID-19 Update 
Where patients, partners, and quality matter
For over 75 years, Lannett has been proudly providing high-quality, affordable generic pharmaceutical products to patients who depend on them.
What product are you looking for?
Patient Support
We manufacture over 100 unique pharmaceutical product families for a wide range of therapeutic areas, with many more in development. Our philosophy? Patients first.
Our Approach
Many of our patients will never know they are taking one of our medicines. But we know. That’s why we strive for the highest quality standards in our pharmaceutical products.
Careers
Our culture combines a legacy of quality with an appetite for innovation. We’re looking for motivated, engaged individuals to help make the medicines that save and enhance lives.
Spotlight
April 1, 2021
Lannett Submits ANDA For Generic ADVAIR DISKUS®
Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Abbreviated New Drug Application (ANDA) for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) to the U.S. Food and Drug Administration (FDA), by its strategic alliance partner, Respirent Pharmaceuticals Co. Ltd. The product is the generic equivalent of ADVAIR DISKUS® of GlaxoSmithKline. Total U.S. sales of the product, according to IQVIA market, were approximately $3 billion for the 12 months ending February 2021, although actual generic market values are expected to be lower.
ADVAIR DISKUS® and Flovent® Diskus® are registered trademarks of GlaxoSmithKline.